肿瘤/正常组织剂量比对90Y选择性内放射治疗疗效评估的作用
本研究纳入39例接受90Y微球治疗的肝肿瘤患者,术后行PET/CT剂量学计算,以MRI mRECIST标准评估疗效。完全缓解组平均T/N剂量比为24.91,显著高于进展组的6.69。提示T/N剂量比可用于预测治疗反应,但进展病例数有限且未校正部分容积效应,需进一步研究。
要点
- 完全缓解组T/N剂量比显著高于进展组,提示其可用于预测疗效。
- 治疗后90Y PET/CT可计算肿瘤与正常组织剂量并获取T/N比值。
- 进展组病例数有限且未校正部分容积效应,结果需谨慎解读。
核心结论
- 完全缓解患者的T/N剂量比显著高于进展患者,T/N剂量比可用于评估90Y微球治疗后的疗效反应。
研究设计与样本
- 单中心研究,纳入39例接受90Y微球肝局部治疗的患者(女7例、男32例,平均年龄68.3±7.6岁),治疗后行PET/CT成像,采用低剂量非诊断CT做衰减校正与定位,采集15分钟,重建矩阵200×200×75 mm、体素4.07×4.07×3.00 mm。
- 采用已知90Y活度的局部沉积法进行剂量学计算,手动勾画肿瘤与全肝感兴趣区、自动生成正常组织感兴趣区。
- 以治疗后1个月及之后每3个月MRI的mRECIST标准评估疗效作为参考。
诊断标准与关键数值
- 39例患者平均肝脏剂量55.17±26.04 Gy、肿瘤剂量911.87±866.54 Gy、正常组织剂量47.79±20.47 Gy。
- 31例(79%)完全缓解,8例(21%)疾病进展。
- 完全缓解组平均T/N剂量比为24.91(范围3.09-80.12),进展组为6.69(范围0.36-14.75),进展组显著更低。
临床应用与阅片要点
- 90Y微球治疗后可行PET/CT剂量学计算,T/N剂量比可作为预测疗效的参考指标。
- 阅片报告时可关注肿瘤与正常组织剂量比值,但需注意部分容积效应对小病灶剂量准确性的影响。
局限性
- 进展病例数有限。
- 剂量学计算未考虑部分容积效应。
- 作者指出需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The purpose of our work is to assess the role of tumour-to-normal tissue (T/N) dosimetry ratios for predicting response in patients undergoing locoregional therapy to the liver with 90Y microspheres.
METHODS: A total of 39 patients (7 female:32 male, mean age 68.3 ± 7.6 years), underwent positron emission tomography (PET)/CT imaging after treatment with 90Y microspheres. For attenuation correction and localization of the 90Y microspheres, the low-dose, non-diagnostic CT images from PET/CT were used. The acquisition took 15 min and the reconstruction matrix size was 200 × 200 × 75 mm and voxel size of 4.07 × 4.07 × 3.00 mm. For dosimetry calculations, the local deposition method with known activity of 90Y was used. For each patient, regions of interest for tumour(s) and whole liver were manually created; the normal tissue region of interest was created automatically. mRECIST criteria on MRI done at 1 month post-treatment and subsequently every 3 months after 90Y treatment, were used to assess response.
RESULTS: For 39 patients, the mean liver, tumour and normal tissue doses (mean ± SD) were, 55.17 ± 26.04 Gy, 911.87 ± 866.54 Gy and 47.79 ± 20.47 Gy, respectively. Among these patients, 31 (79%) showed complete response (CR) and 8 (21%) showed progression of disease (PD). For patients with CR, the mean T/N dose ratio obtained was 24.91 (range 3.09-80.12) and for patients with PD, the mean T/N dose ratio was significantly lower, at 6.69 (range 0.36-14.75).
CONCLUSION: Our data show that patients with CR have a statistically higher T/N dose ratio than those with PD. Because, the number of PD cases was limited and partial volume effect was not considered, further investigation is warranted.
ADVANCES IN KNOWLEDGE: T/N dosimetry ratios can be used for assessing response in patients undergoing locoregional therapy to the liver with 90Y microspheres.
引用
- Knešaurek, Martinez, Ghesani, et al. Tumour-to-normal tissue (T/N) dosimetry ratios role in assessment of 90Y selective internal radiation therapy (SIRT). Br J Radiol. 2021. PMID: 34762514. doi:10.1259/bjr.20210294
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。